I agree that this site is using cookies. You can find further informations here.
X
Amengual, Jennifer E.
100  results:
Search for persons X
?
1

Quantitation of tazemetostat in human plasma using liquid c..:

Orleni, Marco ; Parise, Robert A. ; Holleran, Julianne L....
Biomedical Chromatography.  38 (2024)  7 - p. , 2024
Link: https://doi.org/10.1002/..
 
?
2

Context-defined cancer co-dependency mapping identifies a f..:

Chen, Xiao ; Li, Yinglu ; Zhu, Fang...
Nature Communications.  14 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
3

Targeting CD38 with Daratumumab Plus Chemotherapy for Patie..:

Ryu, Yun Kyoung ; Ricker, Edd C. ; Soderquist, Craig R....
Journal of Clinical Medicine.  11 (2022)  16 - p. 4928 , 2022
Link: https://doi.org/10.3390/..
 
?
4

First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a H..:

Amengual, Jennifer E. ; Lue, Jennifer K. ; Ma, Helen...
The Oncologist.  26 (2021)  3 - p. 184-e366 , 2021
Link: https://doi.org/10.1002/..
 
?
5

Hypomethylating Agents in Lymphoma:

Cogan, Jacob C. ; Liu, Yuxuan ; Amengual, Jennifer E.
Current Treatment Options in Oncology.  21 (2020)  8 - p. , 2020
Link: https://doi.org/10.1007/..
 
?
6

Chromatin-Remodeled State in Lymphoma:

Liu, Yuxuan ; Gonzalez, Yulissa ; Amengual, Jennifer E.
Current Hematologic Malignancy Reports.  14 (2019)  5 - p. 439-450 , 2019
Link: https://doi.org/10.1007/..
 
?
7

Multicentre retrospective study of intravascular large B‐ce..:

Geer, Marcus ; Roberts, Emily ; Shango, Maryann...
British Journal of Haematology.  186 (2019)  2 - p. 255-262 , 2019
Link: https://doi.org/10.1111/..
 
?
8

Emerging EZH2 Inhibitors and Their Application in Lymphoma:

Lue, Jennifer K. ; Amengual, Jennifer E.
Current Hematologic Malignancy Reports.  13 (2018)  5 - p. 369-382 , 2018
Link: https://doi.org/10.1007/..
 
?
9

The Future of Combination Therapies for Peripheral T Cell L..:

Ma, Helen ; Davarifar, Ardy ; Amengual, Jennifer E.
Current Hematologic Malignancy Reports.  13 (2018)  1 - p. 13-24 , 2018
Link: https://doi.org/10.1007/..
 
?
10

A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclo..:

Sawas, Ahmed ; Farber, Charles M. ; Schreeder, Marshall T....
British Journal of Haematology.  177 (2017)  2 - p. 243-253 , 2017
Link: https://doi.org/10.1111/..
 
?
11

Therapeutic Options for Aggressive T-Cell Lymphomas:

Lue, Jennifer K. ; Kress, Anna ; Amengual, Jennifer E.
Current Hematologic Malignancy Reports.  12 (2017)  4 - p. 269-281 , 2017
Link: https://doi.org/10.1007/..
 
?
12

Brentuximab vedotin and bendamustine produce high complete ..:

Kalac, Matko ; Lue, Jennifer K. ; Lichtenstein, Emily...
British Journal of Haematology.  180 (2016)  5 - p. 757-760 , 2016
Link: https://doi.org/10.1111/..
 
?
13

High rate of complete responses to immune checkpoint inhibi..:

Falchi, Lorenzo ; Sawas, Ahmed ; Deng, Changchun...
Journal of Hematology & Oncology.  9 (2016)  1 - p. , 2016
Link: https://doi.org/10.1186/..
 
?
14

The combination of hypomethylating agents and histone deace..:

Marchi, Enrica ; Zullo, Kelly M. ; Amengual, Jennifer E....
British Journal of Haematology.  171 (2015)  2 - p. 215-226 , 2015
Link: https://doi.org/10.1111/..
 
?
15

Epigenetics and Lymphoma: Can We Use Epigenetics to Prime o..:

Lue, Jennifer K. ; Amengual, Jennifer E. ; O'Connor, Owen A.
Current Oncology Reports.  17 (2015)  9 - p. , 2015
Link: https://doi.org/10.1007/..
 
1-15